





# Snoring and Beyond: the Clinical Implications of Sleep Disordered Breathing in Pregnancy

Sushmita Pamidi, MD MSc FRCPC
Assistant Professor of Medicine
Division of Respiratory Medicine
Department of Medicine
McGill University




### Financial Interest Disclosure

(over the past 24 months)

Sushmita Pamidi


No disclosures

### **Factors Influencing Sleep in Pregnancy**



### Sleep Complaints in Pregnancy


Sleep questionnaires administered in early pregnancy (6-20 weeks) and in



Facco et al., Obstetrics & Gynecology 2010

# Change in Self-Reported Total Sleep Time During Pregnancy






### Mallampati Grade Increases As Pregnancy Progresses





### **Upper Airway Size in Pregnancy**

#### Acoustic reflectometry:




OPJ: Oropharyngeal junction





### **Nocturnal Fluid Shifts and Sleep Apnea**




## Symptoms of Sleep-Disordered Breathing (SDB) in Men vs. Women

Symptom	Odds Ratio
Loud Snoring	1.8
Snoring disturbs others	2.4
Snorts/gasps	1.9

 Women are 2-3x less likely to report symptoms of snoring, gasping and apnea compared to men (adjusted for RDI)

### Symptoms of OSA Increase Over the Course of Pregnancy




#### **OBSTETRICS**


## NuMoM2b Sleep-Disordered Breathing study: objectives and methods

Francesca L. Facco, MD, MS; Corette B. Parker, DrPH; Uma M. Reddy, MD, MPH; Robert M. Silver, MD; Judette M. Louis, MD, MPH; Robert C. Basner, MD; Judith H. Chung, MD, PhD; Frank P. Schubert, MD, MS; Grace W. Pien, MD, MSCE; Susan Redline, MD, MPH; Daniel R. Mobley, RPSGT; Matthew A. Koch, MD, PhD; Hyagriv N. Simhan, MD, MS; Chia-Ling Nhan-Chang, MD, MS; Samuel Parry, MD; William A. Grobman, MD, MBA; David M. Haas, MD, MS; Deborah A. Wing, MD; Brian M. Mercer, MD; George R. Saade, MD; Phyllis C. Zee, MD, PhD

- Prospective cohort of 10,037 nulliparous women with singleton gestations across 8 sites
- Sleep Disordered Breathing substudy recruited 3,702 women to undergo objective level 3 home sleep studies (Sept 2013):
  - Visit 1: 6-15 weeks GA
  - Visit 2: 22-31 weeks GA



# Different Scoring Criteria and AHI Cut-offs Affect Prevalence



Prospective healthy cohort of 3<sup>rd</sup> trimester women (n=234) using Chicago scoring criteria


# Relationship between Symptoms and PSG-based Diagnosis of SDB in Pregnancy

Proportion			
Diagnostic test result parameter (%, 95% CI)	AHI≥5	AHI≥10	AHI≥15
First trimester			
Sensitivity	37.7 (28.8 to 47.3)	41.7 (27.6 to 56. 8)	52.0 (31.3 to 72.2)
Specificity	83.0 (71.0 to 91.6)	73.6 (65.0 to 81.0)	73.0 (65.1 to 80.0)
Third trimester			
Sensitivity	57.1 (47.4 to 66.4)	70.6 (56.2 to 82.5)	76.9 (56.3 to 91.0)
Specificity	63.2 (49.3 to 75.5)	58.5 (49.0 to 67.5)	54.5 (46.0 to 62.9)
0.1			<b>─</b> ■3rd TM
АНІ	<5 5≤AHI<10	10≤AHI<15	AHI≥15

### **Screening for SDB in Pregnancy**

- Questionnaires of sleepiness (Epworth sleepiness scale; ESS) are not sensitive or specific for SDB, likely due to the high prevalence of daytime sleepiness (up to 65% of pregnant women in the third trimester)
- the Berlin Questionnaire has moderate sensitivity (pooled 0.66) and specificity (pooled 0.63) for predicting SDB
- STOP-Bang has the best specificity (0.85) in the third trimester but has poor sensitivity at only 0.53

# Performance of ESS and Berlin in Screening for OSA in Pregnancy



Frequent snoring (> 3x/wk) and AHI > 5: OR 4.4

#### 4 variable prediction:


pre-pregnancy BMI, age, chronic hypertension (15 points) and frequent snoring (15 points) → AUC 0.85.

A score of 75 (upper left corner) gave a SN 86% and SP of 74%

# Pregnancy is Characterized by "milder" OSA


	Third trimester	No 3rd r trimester OSA (n=77)	p Value
Baseline BMI, kg/m² (SD)	34.1 (7.9)	28.5 (6.3)	0.002
Gestational weight gain, kg (SD)	7.0 (5.2)	9.6 (5.5)	0.034
Third trimester BMI, kg/m <sup>2</sup> (SD)	37.0 (7.4)	32.1 (5.5)	0.003
Third trimester Epworth score (SD)	10.6 (4.1)	9.2 (4.0)	0.129
First trimester AHI, events/h (SD, median)	4.08 (4.55, 2.6	5) 1.34 (1.74, 0.7)	
Third trimester AHI, events/h (SD, median)	10.97 (7.69, 8.3	3) 1.11 (1.24, 0.6)	
Apnoea Index	1.79 (3.62)	0.12 (0.25)	
Hypopnoeas with arousal	7.30 (5.26)	0.84 (1.08)	
Hypopnoeas with 3% desaturation	1.89 (2.33)	0.15 (0.37)	


# Flow-limitation occurs ~70% of time in preeclampsia patients



-RDI in this group was less than 10/hr

### Sleep Apnea Risk Decreases Postnatally






### What is the optimal diagnostic tool?

- 20-30% of pregnant women snore by the 3<sup>rd</sup> trimester
- No standardized way to assess snoring
- 4 million pregnancies/year (US) and 500,000 pregnancies/year (Canada)
- Large diagnostic burden to use level I or II type testing routinely
- Should we include assessments of flow limitation?
- Type III testing?

## Level III Study



- -Convenient, in-home testing
- -However, unable to detect hypopneas with arousals


## SDB in Pregnancy and Health Outcomes

#### **OBSTETRICS**

www.AJOG.org

## Maternal sleep-disordered breathing and adverse pregnancy outcomes: a systematic review and metaanalysis

Sushmita Pamidi, MD; Lancelot M. Pinto, MD, MSc; Isabelle Marc, MD; Andrea Benedetti, PhD; Kevin Schwartzman, MD, MPH; R. John Kimoff, MD



# Obstructive sleep apnoea and its association with gestational hypertension

K. Champagne\*, K. Schwartzman\*, L. Opatrny\*, P. Barriga\*, L. Morin\*, A. Mallozzi\*, A. Benjamin\* and R.J. Kimoff<sup>§</sup>


TABLE 4	Adjusted odds ratio (OR) for each variable and its association with gestational hypertension					
Variables		Adjusted OR (95% CI)	p-values			
Sleep apnoea# versus no sleep 7.5 (3.5–16.2) <0.0001 apnoea						
BMI per 1 kg·m <sup>-2</sup> increase 1.2 (1.1–1.4) 0.001						
Maternal age	nal age per 1-yr increase 1.2 (0.95–1.4) 0.14					
Pregnancy st	atus					
Previous pre	gnancy but no live birth	12.8 (3.5-46.0)	< 0.0001			
First pregna	ncy	3.4 (0.25-45.5)	0.35			
Previous live	e birth <sup>¶</sup>	1				
Gestational a	ge					
20–27 week	s	1.1 (0.4-3.2)	0.80			
27–34 week	S	0.8 (0.5-1.2)	0.32			
>34 weeks <sup>¶</sup> 1						

Champagne et al., ERJ 2009

#### **OBSTETRICS**

### Maternal sleep-disordered breathing and adverse pregnancy outcomes: a systematic review and metaanalysis

Sushmita Pamidi, MD; Lancelot M. Pinto, MD, MSc; Isabelle Marc, MD; Andrea Benedetti, PhD; Kevin Schwartzman, MD, MPH; R. John Kimoff, MD



### Sleep-Disordered Breathing and Gestational Diabetes Mellitus

A meta-analysis of 9,795 participants enrolled in epidemiological observational studies

Miguel Angel Luque-Fernandez, phd<sup>1</sup> Paul A. Bain, phd<sup>2</sup> Bizu Gelaye, phd<sup>1</sup> Susan Redline, md, mph<sup>3</sup> Michelle A. Williams, scd<sup>1</sup> Diabetes Care 36:3353-3360, 2013

Author, (year)		Adjusted OR (95%CI)	%, Weight
BMI adjusted:			
Bourjeily G. (2010)	-	2.10 (1.30, 3.40)	23.34
Facco F. (2010)		6.90 (1.40, 33.95)	7.06
Reutrakul S. (2011)		3.40 (1.31, 8.85)	13.87
Chen Y-H. (2012)		1.63 (1.07, 2.48)	24.69
Subtotal (I-squared = 32.6%, p = 0.217)		2.17 (1.45, 3.25)	68.96
Analysis stratified by BMI:			
Qiu C. (2010)		<b>-</b> 6.90 (2.87, 16.59)	15.17
O'Brien L. (2012)	-	4.12 (1.78, 9.53)	15.86
Subtotal (I-squared = 0.0%, p = 0.405)		5.27 (2.87, 9.66)	31.04
Pooled summary OR:			
Overall (I-squared = 61.2%, p = 0.024)		3.06 (1.89, 4.96)	100.00
NOTE: Weights are from random-effects analysis			
	1 3	34	

#### OSA AND SEVERE MATERNAL-INFANT MORBIDITY/MORTALITY IN THE USA

http://dx.doi.org/10.5665/sleep.3644

## Obstructive Sleep Apnea and Severe Maternal-Infant Morbidity/Mortality in the United States, 1998-2009

Judette M. Louis, MD, MPH1; Mulubrhan F. Mogos, PhD2; Jason L. Salemi, MPH2; Susan Redline, MD, MPH3; Hamisu M. Salihu, MD, PhD1,2

SLEEP 2014;37(5):843-849

- ~55 million pregnancy-related hospital discharges using 1998-2009 annual data from the Nationwide Inpatient Sample (NIS)
- Used ICD-9-CM codes to identify maternal-fetal complications and diagnosis of OSA
- OSA significantly associated with complications, including GDM

		R	atea		OR (9	5% CI)	
Ou	tcomes	OSA	No OSA	Model 1 <sup>b</sup>	Model 2 <sup>c</sup>	Model 3d	Model 4 <sup>e</sup>
N	laternal, pregnancy-related						
	Cesarean section <sup>f</sup>	430.51	251.28	2.26 (2.09-2.43)	2.05 (1.87-2.24)	1.29 (1.17-1.42)	1.12 (1.01-1.23)
	Gestational diabetes <sup>9</sup>	191.29	45.08	5.03 (4.50-5.62)	3.85 (3.43–4.31)	2.02 (1.79–2.28)	1.89 (1.67–2.14)

Adjusted for obesity

Adjusted for comorbidities


#### Original Research

#### Association Between Sleep-Disordered Breathing and Hypertensive Disorders of Pregnancy and Gestational Diabetes Mellitus


Francesca L. Facco, MD, MSCI, Corette B. Parker, DrPH, Uma M. Reddy, MD, MPH, Robert M. Silver, MD, Matthew A. Koch, MD, PhD, Judette M. Louis, MD, MPH, Robert C. Basner, MD, Judith H. Chung, MD, PhD, Chia-Ling Nhan-Chang, MD, Grace W. Pien, MD, MSCE, Susan Redline, MD, MPH, William A. Grobman, MD, MBA, Deborah A. Wing, MD, MBA, Hyagriv N. Simhan, MD, David M. Haas, MD, MS, Brian M. Mercer, MD, Samuel Parry, MD, Daniel Mobley, RPSGT, Shannon Hunter, MS, George R. Saade, MD, Frank P. Schubert, MD, MS, and Phyllis C. Zee, MD, PhD

		Crude	OR	Adjusted OR	
All Apneas and Hypopneas With 3% Oxygen Desaturation/h (AHI)	n/N (%)	Estimate (95% CI)	P	Estimate (95% CI)	P
Preeclampsia					
Early pregnancy (n=3,131) Less than 5 (referent)	170/3,017 (5.6)	1.00	<.001	1.00	.03
5 or greater	16/114 (14.0)	2.73 (1.58-4.74)		1.94 (1.07–3.51)	* pilotik
0 (referent)	42/763 (5.5)	1.00	.004	1.00	.16
Greater than 0 to less than 5	128/2,254 (5.7)	1.03 (0.72-1.48)	Trend tests:	0.96 (0.66-1.39)	
5 to less than 15	14/105 (13.3)	2.64 (1.39-5.02)	.02 linear	1.79 (0.89-3.61)	
15 or greater	2/9 (22.2)	4.90 (0.99-24.34)	.50 quadratic	2.74 (0.51-14.73)	


## Potential Causal Pathways Linking Maternal Sleep-Disordered Breathing and Gestational Diabetes and Gestational Hypertension/Pre-eclampsia



Izci-balserak B, Pien GW. The relationship and potential mechanistic pathways between sleep disturbances and maternal hyperglycemia. *Curr Diab Rep.* 2014 Feb;14(2):459.



#### **Maternal SDB and Low Infant Birth Weight**



Pamidi S, Pinto LM, Marc I, Benedetti A, Schwartzman K, Kimoff RJ. Maternal sleep-disordered breathing and adverse pregnancy outcomes: a systematic review and metaanalysis. *Am J Obstet Gynecol.* 2014 Jan;210(1):52.



### Effects of Maternal Obstructive Sleep Apnoea on Fetal Growth: A Prospective Cohort Study

	Cases (n = 14)	Controls (n = 27)	P value
Respiratory Disturbance Index	7.9 (6.1–13.8)	2.2 (1.3–3.5)	<.001
Apnoea Hypopnoea Index	6.2 (4.9–11.7)	1.4 (0.6–2.6)	<.001
Oxygen Desaturation Index ≥3%	(3.4 (1.5–9.4)	0.4 (0.1–1.0)	<.001
Oxygen Desaturation Index ≥4%	1.9 (0.7–5.1)	0.1 (0.0-0.3)	<.001
Number of desaturations ≥3%	16.5 (9.3–38.5)	3.0 (1.0-5.0)	<.001
Number of desaturations ≥4%	9.5 (4.0-23.5)	1.0 (0.0-2.0)	<.001
Largest oxygen desaturation (%	)6 (5.0–8.3)	4 (3.0–5.0)	.001
Minimum O2 (%)	90 (88–90.3)	91 (90–93)	.044
%Total Sleep Time below 95%	34.7 (12.0-58.2)	17.2 (4.4–56.5)	.25
%Total Sleep Time below 90%	0.1 (0-0.1)	0 (0-0)	.003

customised centile >33% between 32 weeks and term)					
Birthweight <10 <sup>th</sup> centile	2 (14%)	3 (11%)	1		
Fall in customised centile >33% between 32 weeks and term 4 (29%) 0 (0%) <0.01					
Apgar ≤7 at 5 min	0	1 (4%)	1.0		
Admission SCN/NICU	0	1 (3.7%)	1.0		

#### OSA AND SEVERE MATERNAL-INFANT MORBIDITY/MORTALITY IN THE USA

http://dx.doi.org/10.5665/sleep.3644

### Obstructive Sleep Apnea and Severe Maternal-Infant Morbidity/Mortality in the United States, 1998-2009


Judette M. Louis, MD, MPH1; Mulubrhan F. Mogos, PhD2; Jason L. Salemi, MPH2; Susan Redline, MD, MPH3; Hamisu M. Salihu, MD, PhD1,2

<sup>1</sup>Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Morsani College of Medicine, University of South Florida, Tampa, FL; <sup>2</sup>Maternal and Child Health Comparative Effectiveness Research Group, Department of Epidemiology and Biostatistics, College of Public Health, University of South Florida, Tampa, FL; <sup>3</sup>Division of Sleep Medicine, Department of Medicine, Harvard Medical School, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center, Boston, MA


	R	ate <sup>a</sup>	OR (95% CI)			
Outcomes	OSA	No OSA	Model 1 <sup>b</sup>	Model 2 <sup>c</sup>	Model 3 <sup>d</sup>	Model 4 <sup>e</sup>
Fetal/infant						
Early-onset delivery	101.15	65.33	1.62 (1.43-1.84)	1.40 (1.24-1.61)	1.32 (1.16-1.50)	1.20 (1.06-1.37)
Poor fetal growth	21.88	15.92	1.39 (1.10-1.74)	1.26 (1.01-1.59)	1.28 (1.02-1.62)	1.21 (0.96-1.53)
Stillbirth	8.05	6.29	1.28 (0.84–1.95)	1.04 (0.68–1.58)	1.07 (0.70-1.62)	1.01 (0.66–1.53)

# Maternal sleep-disordered breathing and the risk of delivering small for gestational age infants: a prospective cohort study


Sushmita Pamidi, <sup>1</sup> Isabelle Marc, <sup>2</sup> Gabrielle Simoneau, <sup>3,4</sup> Lorraine Lavigne, <sup>1</sup> Allen Olha, <sup>1</sup> Andrea Benedetti, <sup>3,4</sup> Frédéric Sériès, <sup>5</sup> William Fraser, <sup>6</sup> François Audibert, <sup>6</sup> Emmanuel Bujold, <sup>2</sup> Robert Gagnon, <sup>7</sup> Kevin Schwartzman, <sup>1,3,4</sup> R John Kimoff <sup>1</sup>



## Animal Studies




- pups of rats exposed to intermittent hypoxia
- ☐ pups of rats in room air during gestation



Iqbal et al., AJOG 2013

## Fetoplacental Hypoxia

Carbonic Anhydrase IX (Tissue Hypoxia Marker)



## Treatment Options


- Lack of RCTs
- CPAP lower compliance?
  - milder OSA
  - inability to lie supine
  - nasal rhinitis/congestion
- Role for alternatives to therapy: oral appliances?

### Sleep disordered breathing and pregnancy


N Edwards, P G Middleton, D M Blyton, C E Sullivan

Thorax 2002;57:555-558


Pre-eclampsia patients treated with auto-PAP



## Maternal SDB and Fetal Activity




NREM sleep



REM sleep


### **Future Research Directions**

- Comparing ambulatory vs. level I/II studies against health outcomes
- Role of biomarkers and screening in targeting high risk women; at what stage of pregnancy should OSA testing occur?
- Mechanisms of SDB in pregnancy
- Natural history of SDB in females (pre- and post- pregnancy)
- Randomized-controlled trials
  - CPAP and oral appliances



<sup>\*</sup> Possible only if participant has not delivered; If continuous glucose monitoring (CGM) not available on any visits, the most recent downloaded capillary blood glucose (CBG) measurements will be used as surrogate measures of glycemia

## Oral Appliances in Pregnancy



Léa Drouin-Gagné, Nelly Huynh, Sushmita Pamidi, John Kimoff

## Acknowledgements

- R. John Kimoff, MD
- Isabelle Marc, MD PhD
- Lorraine Lavigne, RN
- Allen Olha, RPSGT
- Lancelot Pinto, MD
- Nelly Huynh, PhD
- Léa Drouin-Gagné
- Ahamed Khalyfa



Fonds de la recherche en santé

Québec



Centre universitaire de santé McGill

